[Gyrase inhibitors modify metabolising processes in the liver].
Staib
A H
AH
Harder
S
S
Papenburg
A
A
Stille
W
W
D002110:Caffeine / Q000378:metabolism; D002939:Ciprofloxacin / Q000494:pharmacology; D004250:DNA Topoisomerases, Type II / Q000494:pharmacology; D015365:Enoxacin; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D009287:Naphthyridines / Q000494:pharmacology; D009643:Norfloxacin / Q000494:pharmacology; D015242:Ofloxacin; D010078:Oxazines / Q000494:pharmacology; D010876:Pipemidic Acid / Q000494:pharmacology; D059005:Topoisomerase II Inhibitors
D009287:Naphthyridines; D010078:Oxazines; D059005:Topoisomerase II Inhibitors; D015365:Enoxacin; D002110:Caffeine; D002939:Ciprofloxacin; D015242:Ofloxacin; D004250:DNA Topoisomerases, Type II; D010876:Pipemidic Acid; D009643:Norfloxacin
Gyrasehemmer beeinflussen Metabolisierungsprozesse in der Leber.